Tue, 06th Nov 2018 16:29
LONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said VP Drug Development Chief Medical Officer Matti Karvonen acquired shares in the biopharmaceutical company.
In a transaction on October 26, Karvonen bought 20,000 shares at a price of 82.90 pence per share, worth GBP16,580.
Shares in Faron Pharmaceuticals were trading 0.7% higher on Tuesday at 76.50p each.
(Alliance News) - Faron Pharmaceuticals Ltd on Monday noted a positive read-out regarding the ongoing Bexmab trial on myelodysplastic syndrome, a form...
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Allia...
(Sharecast News) - Faron Pharmaceuticals announced on Tuesday that it has extended its agreement with lender IPF to ensure continued financial support...
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it appointed a new interim chief financial officer to replace the outgoing James O'Brien.
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would ...
Faron Pharmaceuticals (FARN)